{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemophilia+A+and+B&page=2",
    "query": {
      "condition": "Hemophilia A and B",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemophilia+A+and+B&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T20:37:18.850Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07285460",
      "title": "A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia"
      ],
      "interventions": [
        {
          "name": "Fitusiran",
          "type": "DRUG"
        },
        {
          "name": "Clotting factor concentrates (CFC) or bypassing agents (BPA)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Antithrombin concentrate (ATIIIC)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "11 Years",
        "sex": "MALE",
        "summary": "1 Year to 11 Years · Male only"
      },
      "enrollment_count": 85,
      "start_date": "2025-12-18",
      "completion_date": "2031-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-06-10T20:37:18.850Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Orange, California • Las Vegas, Nevada + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07285460"
    },
    {
      "nct_id": "NCT01620801",
      "title": "Hemophilia B Gene Therapy With AAV8 Vector",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "AAV8-hFIX19",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Spark Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2012-10",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2019-03-12",
      "last_synced_at": "2026-06-10T20:37:18.850Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01620801"
    },
    {
      "nct_id": "NCT03549871",
      "title": "A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia"
      ],
      "interventions": [
        {
          "name": "Fitusiran",
          "type": "DRUG"
        },
        {
          "name": "BPA prophylaxis",
          "type": "DRUG"
        },
        {
          "name": "Factor (FVIII or FIX) prophylaxis",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 80,
      "start_date": "2018-07-25",
      "completion_date": "2022-03-25",
      "has_results": true,
      "last_update_posted_date": "2023-02-06",
      "last_synced_at": "2026-06-10T20:37:18.850Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03549871"
    },
    {
      "nct_id": "NCT03307980",
      "title": "Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "PF-06838435 (formerly SPK-9001)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 21,
      "start_date": "2017-06-22",
      "completion_date": "2029-10-25",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-06-10T20:37:18.850Z",
      "location_count": 17,
      "location_summary": "Sacramento, California • Metairie, Louisiana • New Orleans, Louisiana + 4 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03307980"
    },
    {
      "nct_id": "NCT02740335",
      "title": "Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Significant Bleeding Risk"
      ],
      "interventions": [
        {
          "name": "Octaplex",
          "type": "DRUG"
        },
        {
          "name": "Beriplex P/N (Kcentra)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2017-06-08",
      "completion_date": "2022-02-23",
      "has_results": true,
      "last_update_posted_date": "2023-03-08",
      "last_synced_at": "2026-06-10T20:37:18.850Z",
      "location_count": 22,
      "location_summary": "Aurora, Colorado • New Haven, Connecticut • Miami, Florida + 14 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02740335"
    },
    {
      "nct_id": "NCT05605678",
      "title": "Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia a",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "ApcinteX Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 108,
      "start_date": "2022-12-09",
      "completion_date": "2024-11-29",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-06-10T20:37:18.850Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Greenville, South Carolina",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05605678"
    },
    {
      "nct_id": "NCT02053792",
      "title": "A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "rIX-FP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "MALE",
        "summary": "Up to 70 Years · Male only"
      },
      "enrollment_count": 97,
      "start_date": "2014-02-06",
      "completion_date": "2021-06-02",
      "has_results": true,
      "last_update_posted_date": "2022-07-14",
      "last_synced_at": "2026-06-10T20:37:18.850Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02053792"
    },
    {
      "nct_id": "NCT00486278",
      "title": "Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia A",
        "Haemophilia B"
      ],
      "interventions": [
        {
          "name": "eptacog alfa (activated)",
          "type": "DRUG"
        },
        {
          "name": "vatreptacog alfa (activated)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 51,
      "start_date": "2007-06",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2017-03-07",
      "last_synced_at": "2026-06-10T20:37:18.850Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00486278"
    },
    {
      "nct_id": "NCT01561391",
      "title": "Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia A With Inhibitors",
        "Haemophilia B With Inhibitors"
      ],
      "interventions": [
        {
          "name": "activated recombinant human factor VII",
          "type": "DRUG"
        },
        {
          "name": "factor IX",
          "type": "OTHER"
        },
        {
          "name": "factor VIII",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "1998-04",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-06-10T20:37:18.850Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01561391"
    },
    {
      "nct_id": "NCT00108797",
      "title": "Trial of NovoSeven® in Haemophilia - Joint Bleeds",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia A With Inhibitors",
        "Haemophilia B With Inhibitors"
      ],
      "interventions": [
        {
          "name": "eptacog alfa (activated)",
          "type": "DRUG"
        },
        {
          "name": "Feiba VH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "20 Years",
        "sex": "MALE",
        "summary": "Up to 20 Years · Male only"
      },
      "enrollment_count": 42,
      "start_date": "2001-09",
      "completion_date": "2006-02",
      "has_results": false,
      "last_update_posted_date": "2017-01-12",
      "last_synced_at": "2026-06-10T20:37:18.850Z",
      "location_count": 20,
      "location_summary": "Little Rock, Arkansas • Berkeley, California • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00108797"
    }
  ]
}